[A26-74] Burosumab (X-linked hypophosphataemia, 1 month to 1 year) – Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2026
Project no.:
A26-74
Commission:
Commission awarded on 23.06.2026 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Treatment of X-linked hypophosphataemia (XLH) in infants from 1 month to 1 year of age with hypophosphataemia
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
https://doi.org/10.60584/A26-74
| Project no. | Title | Status |
|---|---|---|
| A22-11 | Burosumab (X-linked hypophosphataemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-12 | Burosumab (X-linked hypophosphataemia, = 18 years) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-88 | Burosumab (FGF23-related hypophosphataemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |